New Therapeutic Target for Prostate Cancer.
New research indicates a potential therapeutic target for castration-resistant prostate cancer: RORγ, which is abundant in the disease, can drive androgen receptor hyperactivity. Blocking RORγ with small-molecule antagonists suppresses AR and impedes tumor growth in mice bearing human prostate tumors, including a model resistant to the antiandrogen enzalutamide.